HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

(2021) Ariella B. Hanker et al.   CANCER CELL

Type I Protein Arginine Methyltransferases Overexpression Promotes Transformation and Potentiates Her2/Neu–Driven Tumorigenesis

(2019) Zachary L. Watson et al.   CANCER RESEARCH

Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance

(2019) Alex Pearson et al.   CLINICAL CANCER RESEARCH

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

(2019) Lillian M. Smyth et al.   Cancer Discovery

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

(2018) Luca Gianni et al.   LANCET ONCOLOGY

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

(2018) Zhiqiang Li et al.   CANCER CELL

NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

(2018) Marcus Ruscetti et al.   SCIENCE

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

(2018) Emiliano Cocco et al.   Science Signaling

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

(2017) Mateus de Oliveira Taveira et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

HER2-positive breast cancer

(2017) Sibylle Loibl et al.   LANCET

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

HER2-positive breast cancer is lost in translation: time for patient-centered research

(2017) Isabelle Gingras et al.   Nature Reviews Clinical Oncology

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

(2016) Shom Goel et al.   CANCER CELL

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing

(2016) Ronglai Shen et al.   NUCLEIC ACIDS RESEARCH

Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas

(2016) Saya H. Ebbesen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

(2015) Ian J. Majewski et al.   JOURNAL OF CLINICAL ONCOLOGY

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

(2014) Piro Lito et al.   CANCER CELL

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

(2014) Moriah H. Nissan et al.   CANCER RESEARCH

An Optimized microRNA Backbone for Effective Single-Copy RNAi

(2013) Christof Fellmann et al.   Cell Reports

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

(2012) S. Chandarlapaty et al.   CLINICAL CANCER RESEARCH

Cooperative Activation of PI3K by Ras and Rho Family Small GTPases

(2012) Hee Won Yang et al.   MOLECULAR CELL

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients

(2011) Maurizio Scaltriti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers

(2010) Bhuvanesh Dave et al.   JOURNAL OF CLINICAL ONCOLOGY

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells

(2009) T. W. Miller et al.   CLINICAL CANCER RESEARCH

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

(2009) A. C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells

(2008) A. Vazquez-Martin et al.   ANNALS OF ONCOLOGY

Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer

(2008) C. A. Pratilas et al.   CANCER RESEARCH

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

(2008) Qing-Bai She et al.   PLoS One